Company Overview - Zelluna ASA aims to deliver transformative treatments for advanced solid cancers in a safe and cost-efficient manner globally [3] - The company is pioneering the development of "off the shelf" T cell receptor (TCR) guided natural killer (NK) cell therapies, which offer broad cancer detection capabilities [3] - The lead program targets MAGE-A4 for the treatment of various solid cancers, marking a world's first in TCR-NK therapies [3] Corporate Actions - An extraordinary general meeting held on 9 January 2025 approved a reverse share split in the ratio of 10:1 [1][4] - The last day to include the right to the old shares is 31 March 2025, with the ex-date set for 1 April 2025 and the record date on 2 April 2025 [4] - The company's shares will be transferred to a new ISIN, changing from NO 001 0851603 to NO 001 3524942, effective 1 April 2025 [4] Shareholder Considerations - Radforsk Investeringsstiftelse has agreed to provide necessary shares to round up any fractions to the nearest whole share, ensuring shareholders do not experience a downward adjustment in their holdings [2]
Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of ISIN
Globenewswire·2025-03-27 14:28